Proteomics

Dataset Information

59

Evaluation of Non-Supervised MALDI Mass Spectrometry Imaging Combined to MicroProteomics for Glioma Grade III Classification


ABSTRACT: An integrated diagnosis using molecular features is recommended in the updated World Health Organization (WHO) classification. Our aim was to explore the role of MALDI-Mass spectrometry imaging (MSI) coupled to microproteomics in order to classify anaplastic glioma by integration of clinical data.

INSTRUMENT(S): Q Exactive

ORGANISM(S): Homo sapiens  

TISSUE(S): Brain

DISEASE(S): Brain Cancer

SUBMITTER: Maxence Wisztorski  

LAB HEAD: Michel Salzet

PROVIDER: PXD004437 | Pride | 2016-12-13

REPOSITORIES: pride

altmetric image

Publications

Evaluation of non-supervised MALDI mass spectrometry imaging combined with microproteomics for glioma grade III classification.

Le Rhun Emilie E   Duhamel Marie M   Wisztorski Maxence M   Gimeno Jean-Pascal JP   Zairi Fahed F   Escande Fabienne F   Reyns Nicolas N   Kobeissy Firas F   Maurage Claude-Alain CA   Salzet Michel M   Fournier Isabelle I  

Biochimica et biophysica acta. Proteins and proteomics 20161124 7


An integrated diagnosis using molecular features is recommended in the 2016 World Health Organization (WHO) classification. Our aim was to explore non-targeted molecular classification using MALDI mass spectrometry imaging (MALDI MSI) associated to microproteomics in order to classify anaplastic glioma by integration of clinical data. We used fresh-frozen tissue sections to perform MALDI MSI of proteins based on their digestion peptides after in-situ trypsin digestion of the tissue sections and  ...[more]

Similar Datasets

2015-09-15 | PXD001986 | Pride
2015-09-09 | PXD001984 | Pride
2018-03-19 | PXD004444 | Pride
2013-08-21 | E-GEOD-50013 | ArrayExpress
2014-05-15 | E-GEOD-53965 | ArrayExpress
2014-05-15 | E-GEOD-53966 | ArrayExpress
2016-06-08 | PXD003375 | Pride
2020-05-27 | PXD014679 | Pride
2018-03-15 | PXD008204 | Pride
1000-01-01 | S-EPMC5600086 | BioStudies